Expert Advice on Management of Moderate to Severe Ulcerative Colitis
  • CME
  • CE

LAUNCH TOOL
ACCEPT DISCLAIMER AND LAUNCH TOOL
Enter patient characteristics in this online CCO tool and compare your treatment plan with those of 5 experts.
Anita Afzali, MD, MPH, FACG
Adam Cheifetz, MD
Raymond K. Cross, MD, MS
Millie D. Long, MD, MPH
David A. Schwartz, MD, FACG, AGAF
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Released: October 28, 2020 Expiration: October 27, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recommendations from the latest UC management guidelines regarding next steps for patients with moderate to severely active UC
  • Consider the utility of the latest UC therapies that can better align with patients’ needs for a treatment that is convenient, effective, and safe

Disclaimer

Disclaimer: Access to and use of this Interactive Decision Support Tool titled, “Expert Advice on Management of Moderate to Severe Ulcerative Colitis,” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate clinicians on treating patients with moderate to severe ulcerative colitis. The information provided is based on expert guidance of Anita Afzali, MD, MPH, FACG; Adam Cheifetz, MD; Raymond K. Cross, MD, MS, AGAF, FACG; Millie D. Long, MD, MPH; and David A. Schwartz, MD, FACG, AGAF.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the Expert Advice on Management of Moderate to Severe Ulcerative Colitis” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2020 Clinical Care Options, LLC. All rights reserved.

Acknowledgements

Provided by the American Gastroenterological Association, in collaboration with Clinical Care Options

American Gastroenterological Association (AGA)
4930 Del Ray Avenue
Bethesda, MD 20814
Phone: (301) 654-2055
Fax: (301) 654-5920
Email: member@gastro.org

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

This activity is supported by an educational grant from
Pfizer Inc.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Raymond K. Cross, MD, MS

Professor of Medicine
Division of Gastroenterology and Hepatology
Department of Medicine
University of Maryland School of Medicine
Baltimore, Maryland

Raymond K. Cross, MD, MS, has disclosed that he has received consulting fees from AbbVie, Janssen, Samsung Bioepis, and Takeda and fees for non-CME/CE services from Pfizer.
David A. Schwartz, MD, FACG, AGAF

Professor of Medicine
Department of Gastroenterology
Director, IBD Center
Vanderbilt University
Nashville, Tennessee

David A. Schwartz, MD, FACG, AGAF, has disclosed that he has received consulting fees from AbbVie, Genentech, Gilead Sciences, Janssen, Pfizer, Takeda, and UCB and funds for research support from UCB.
Adam Cheifetz, MD

Director, Center for Inflammatory Bowel Disease
Beth Israel Deaconess Medical Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Adam Cheifetz, MD, has disclosed that he has received funds for research support from Inform Diagnostics and consulting fees from AbbVie, Arena, Bacainn, Grifols, Janssen, Pfizer, Prometheus, Samsung, and Takeda.
Millie D. Long, MD, MPH

Associate Professor of Medicine
Director,
Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
Division of Gastroenterology and Hepatology 
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Millie D. Long, MD, MPH, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, Janssen, Pfizer, Prometheus, Salix, Takeda, Target Pharmasolutions, UCB, and Valeant and funds for research support from Pfizer and Takeda.
Anita Afzali, MD, MPH, FACG

Associate Professor of Medicine
Medical Director, 
OSU Inflammatory Bowel Disease Center
Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease

Division of Gastroenterology, Hepatology and Nutrition
The Ohio State University Wexner Medical Center
Columbus, Ohio

Anita Afzali, MD, MPH, FACG, has disclosed that she has received consulting fees from AbbVie, Celgene/Bristol-Myers Squibb, Janssen, Pfizer, and Takeda; funds for research support from AbbVie, Celgene/Bristol-Myers Squibb, Janssen, Lilly, and Takeda; received fees for non-CME/CE services from AbbVie, Janssen, Pfizer, and Takeda; and received other financial material support from IBD Horizons.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSC, ELS, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Anne Roc, PhD
Director, Scientific Services
Anne Roc, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

The primary target audience for this activity includes gastroenterologists, nurses, nurse practitioners, and other healthcare providers who treat patients with ulcerative colitis.

Goal

The goal of this activity is to improve clinicians’ competence to select effective treatment for patients with moderate to severe ulcerative colitis, including those with difficult-to-treat UC who have failed TNF inhibitor therapy.

Physician Continuing Medical Education

Accreditation Statement

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The AGA Institute designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and the American Gastroenterological Association. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 28, 2020, through October 27, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

CCO slides: current best practice for choosing among biologics and other JAK inhibitors for patients with moderate to severe ulcerative colitis

Released: November 13, 2020

Expert slides from Clinical Care Options (CCO) on optimal management of inflammatory bowel disease (IBD), including ulcerative colitis, Crohn disease

Uma Mahadevan, MD William Sandborn, MD Released: September 22, 2020

New from EULAR 2020, Clinical Care Options (CCO): adults with immune-mediated inflammatory disease report biologic-associated fatigue in Dutch Biologic Monitor

Released: August 13, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue